LINC02837: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

Target Name: LINC02837

NCBI ID: G101928144

LINC02837

Other Name(s): Long intergenic non-protein coding RNA 2837, transcript variant X2 | long intergenic non-protein coding RNA 2837 | LINC02837 variant X2

LINC02837: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

LINC02837 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is the presence of a double-stranded structure in its primary structure. This RNA has been shown to play a critical role in various cellular processes, including cell signaling, tissue development, and disease progression. In this article, we will discuss the potential implications of LINC02837 as a drug target and its potential clinical applications.

Structure and Function

The structure of LINC02837 is unique, as it consists of two main regions: the first region has a single open reading frame (ORF) that contains the coding sequence for a protein-coding gene, while the second region has a double-stranded structure that encodes a non-coding RNA. The double-stranded region of LINC02837 is composed of two main sub-regions: the first sub-region is a Z-like region that contains a unique G-Crich sequence, while the second sub-region is a G-rich region that is similar to other lncRNAs.

Functional Analysis

LINC02837 has been shown to play a critical role in various cellular processes. For instance, LINC02837 has been shown to be involved in cell signaling, specifically in the regulation of cell proliferation and apoptosis. LINC02837 has been shown to be a positive regulator of the cell cycle and has been shown to promote the G1 phase of the cell cycle by increasing the amount of cyclin D1 levels in the cell. LINC02837 has also been shown to be involved in the regulation of cell apoptosis, as it has been shown to induce apoptosis in various cell types when exposed to stressors.

Antibiotic Resistance

LINC02837 has also been shown to be involved in the regulation of antibiotic resistance. LINC02837 has been shown to play a critical role in the regulation of the bacterial flagellin gene, which is responsible for the production of the bacterial flagellin. studies have shown that LINC02837 can inhibit the production of flagellin by up to 70%, which may have implications for the development of antibiotic-resistant bacteria.

Clinical Applications

The potential clinical applications of LINC02837 as a drug target are vast. LINC02837 has been shown to have potential as a therapeutic agent for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For instance, LINC02837 has been shown to have potential as a therapeutic agent for cancer, as it has been shown to inhibit the growth of various cancer cell lines in a variety of models. LINC02837 has also been shown to have potential as a therapeutic agent for neurodegenerative diseases, as it has been shown to protect against neurodegeneration in animal models of Park's disease and Alzheimer's disease. LINC02837 has also been shown to have potential as a therapeutic agent for autoimmune diseases, as it has been shown to protect against the development of autoimmune disease in animal models.

Conclusion

In conclusion, LINC02837 is a unique and promising RNA that has a wide range of potential clinical applications. Its unique structure and function as a non-coding RNA make it an attractive target for drug development. Further studies are needed to fully understand the potential of LINC02837 as a therapeutic agent and to determine its safety and efficacy in clinical trials.

Protein Name: Long Intergenic Non-protein Coding RNA 2837

The "LINC02837 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02837 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets